1900-2000 |
SIU@U Studio Session: BPH and LUTS: Understanding Facts, Debunking Myths Chair: Stavros Gravas, Greece |
|
Speakers: Eugene Goh, Australia |
||
Supported by GlaxoSmithKline |
1155-1310 |
|
Astellas Pharma Lunch Symposium: Match Point in OAB—A New Insight Chair: Adrian Wagg, Canada |
1155-1210 |
Introduction—Code of Play Adrian Wagg |
|
1210-1225 | Coaching Tactics in the Management of OAB: The Key to Success Vincent Tse, Australia |
|
1225-1240 | Oral Treatment for OAB Patients: From Deuce to Advantage Con Kelleher, UK |
|
1240-1255 |
A New Strategy in the Management of OAB: When to Play Doubles Scott MacDiarmid, USA |
|
1255-1310 |
Discussion and Closing Remarks Chair—Faculty—Audience |
1155-1310 |
|
Sanofi Oncology Lunch Symposium: New Perspectives in Tumor Heterogeneity, Therapy, and Resistance in Advanced Prostate Cancer Chair: Christopher P. Evans, USA |
1155 |
Welcome |
|
1155–1215 | Advanced Prostate Cancer Landscape in 2015: When Should Chemotherapy be Used? Amit Bahl, UK |
|
1215–1235 | Facing Today's Challenges in Managing Advanced Prostate Cancer Christopher P. Evans |
|
1235–1255 | Resistance to Androgen Pathway Drugs and Novel Strategies to Overcome it Emmanuel Antonarakis, USA |
|
1255–1310 | Clinical Case, Panel Discussion, and Closing Remarks Christopher P. Evans Emmanuel Antonarakis Amit Bahl |